| Status | Topic selection |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Decision makers have concluded that the clear rationale to not evaluate your product is due to your product being a biosimilar of published TA509. Generic or biosimilar medicines are not considered by NICE if the branded version is recommended in NICE technology appraisal or highly specialised technologies guidance. Please see 3 Topics that are not usually considered by NICE | NICE-wide topic prioritisation: the manual | Guidance | NICE for further information. |
| ID number | 12094 |
Project Team
| Project lead | Danielle Lees |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 September 2024 | Topic selection |
| 10 September 2024 | Topic selection |
For further information on how we select topics for development, please see our page about topic selection